A clinical constraint on lenalidomide-driven TH17 reprogramming

This pattern does not fit a simple exposure-only model.If lenalidomide-induced TH17 reprogramming contributes clinically, it is more likely an enabling condition than a sufficient cause, with host, treatment, or temporal factors gating the phenotype.The cases suggest and constrain candidate modifiers.Glucocorticoid context is one: six combination cycles passed without a flare, and the index flare followed dexamethasone cessation [4], whereas De Novellis et al. observed psoriasis during a dexamethasone-containing regimen [3].Withdrawal cannot explain all three cases.In cohort studies, lesion worsening followed steroid tapering or cessation in 114 of 703 instances, but no documented flare, intensive-care admission, or death was attributed to tapering or cessation; in case series, clinicians attributed 10.8% of psoriasis flares to systemic steroids (95% confidence interval, 4.6%-17.0%)[5].Clinical improvement is also confounded by phototherapy, which preceded marked improvement in all three cases [2-4]; De Novellis et al. attributed later freedom from flares to its local immunomodulatory effects [3].The IL-17 data suggest a reading not developed in the discussion.Lenalidomide increased total IL-17A and IL-17F in culture supernatants while decreasing the percentage of IL-17-expressing cells detected by intracellular flow cytometry.The authors reported a comparable discordance between intracellular staining and bulk measurements under IL-2 neutralization, which they attributed to feedback and secreted-cytokine signaling.The perturbation experiments may dissect it further: Ikaros knockout significantly reduced the frequency of IL-17A-expressing cells, Aiolos knockout did not significantly alter it, and Eos overexpression increased IL-17A-expressing cells and IL-17A/F output alongside other inflammatory cytokines while suppressing IL-10 [1].Because lenalidomide degrades Ikaros and Aiolos while raising Eos, one interpretation is that the fall in IL-17A-positive frequency reflects Ikaros loss, whereas increased secreted IL-17A reflects Eos gain.This decomposition remains inferential because the perturbations were not combined with lenalidomide and attempted IKZF4 knockout did not yield confirmed protein downregulation.

Authors

Institutions

Publication Details

Journal
Cellular and Molecular Life Sciences
Published
2026-11-12
DOI
https://doi.org/10.1007/s00018-026-06502-9
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A clinical constraint on lenalidomide-driven TH17 reprogramming

Ali Mohamed Mousa, Mervat Mahmoud
Cellular and Molecular Life Sciences
Psoriasis: Treatment and Pathogenesis
article

A clinical constraint on lenalidomide-driven TH17 reprogramming

Ali Mohamed Mousa, Mervat Mahmoud
article en

Abstract

This pattern does not fit a simple exposure-only model.If lenalidomide-induced TH17 reprogramming contributes clinically, it is more likely an enabling condition than a sufficient cause, with host, treatment, or temporal factors gating the phenotype.The cases suggest and constrain candidate modifiers.Glucocorticoid context is one: six combination cycles passed without a flare, and the index flare followed dexamethasone cessation [4], whereas De Novellis et al. observed psoriasis during a dexamethasone-containing regimen [3].Withdrawal cannot explain all three cases.In cohort studies, lesion worsening followed steroid tapering or cessation in 114 of 703 instances, but no documented flare, intensive-care admission, or death was attributed to tapering or cessation; in case series, clinicians attributed 10.8% of psoriasis flares to systemic steroids (95% confidence interval, 4.6%-17.0%)[5].Clinical improvement is also confounded by phototherapy, which preceded marked improvement in all three cases [2-4]; De Novellis et al. attributed later freedom from flares to its local immunomodulatory effects [3].The IL-17 data suggest a reading not developed in the discussion.Lenalidomide increased total IL-17A and IL-17F in culture supernatants while decreasing the percentage of IL-17-expressing cells detected by intracellular flow cytometry.The authors reported a comparable discordance between intracellular staining and bulk measurements under IL-2 neutralization, which they attributed to feedback and secreted-cytokine signaling.The perturbation experiments may dissect it further: Ikaros knockout significantly reduced the frequency of IL-17A-expressing cells, Aiolos knockout did not significantly alter it, and Eos overexpression increased IL-17A-expressing cells and IL-17A/F output alongside other inflammatory cytokines while suppressing IL-10 [1].Because lenalidomide degrades Ikaros and Aiolos while raising Eos, one interpretation is that the fall in IL-17A-positive frequency reflects Ikaros loss, whereas increased secreted IL-17A reflects Eos gain.This decomposition remains inferential because the perturbations were not combined with lenalidomide and attempted IKZF4 knockout did not yield confirmed protein downregulation.

Cellular and Molecular Life SciencesVol. 83(1)
Ahmadi Hospital-Kuwait Oil Company (KW)
Good health and well-being
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon